12/24/2025
A Turning Point for Men’s Health
Last week marked a pivotal moment in the future of testosterone therapy.
Three of the most respected leaders in men’s health:
Dr. Mohit Khera,
Dr. Martin Miner,
and Dr. Abraham Morgentaler came together on an FDA expert panel to address long-standing barriers that have limited access to appropriate testosterone care.
This wasn’t about trends or opinions.
It was about science, evidence, and patient outcomes.
Key recommendations presented to the FDA included:
• Ending the “age-related” limitation
Many conditions increase with age—heart disease, hypertension, cancer—and we still treat them to improve quality of life. Testosterone deficiency deserves the same evidence-based approach.
• Removing testosterone from the controlled substances list
No other hormone is classified this way. Removing this designation would significantly reduce unnecessary access barriers for patients.
• Updating treatment thresholds to 350 ng/dL
Allowing therapy when symptoms and clinical signs are present—treating the patient, not just a number.
• Removing outdated prostate cancer warnings
Aligning labeling with current scientific evidence and eliminating fear-based obstacles to appropriate care.
This panel represents more than a policy discussion.
It signals a shift toward modern, data-driven hormone care that prioritizes patient health over outdated assumptions.
At Brite, we stand firmly behind science-led medicine, individualized care, and policies that reflect what the evidence actually shows—not what history has left behind.
Progress happens when medicine evolves.
This was one of those moments.
